22,877 Shares in Humacyte, Inc. (NASDAQ:HUMA) Purchased by XTX Topco Ltd

XTX Topco Ltd purchased a new stake in Humacyte, Inc. (NASDAQ:HUMA) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 22,877 shares of the company’s stock, valued at approximately $110,000.

Several other institutional investors have also recently made changes to their positions in HUMA. Renaissance Technologies LLC boosted its holdings in shares of Humacyte by 693.0% in the 2nd quarter. Renaissance Technologies LLC now owns 600,300 shares of the company’s stock valued at $2,881,000 after buying an additional 524,600 shares during the last quarter. Private Advisor Group LLC grew its position in shares of Humacyte by 15.4% in the 2nd quarter. Private Advisor Group LLC now owns 366,600 shares of the company’s stock valued at $1,760,000 after acquiring an additional 48,976 shares during the period. Endowment Wealth Management Inc. increased its stake in shares of Humacyte by 3.1% during the 2nd quarter. Endowment Wealth Management Inc. now owns 100,518 shares of the company’s stock worth $482,000 after purchasing an additional 3,000 shares during the last quarter. Rhumbline Advisers raised its holdings in shares of Humacyte by 87.8% in the 2nd quarter. Rhumbline Advisers now owns 110,919 shares of the company’s stock valued at $532,000 after purchasing an additional 51,858 shares during the period. Finally, nVerses Capital LLC acquired a new stake in Humacyte in the 2nd quarter valued at about $28,000. Institutional investors and hedge funds own 44.71% of the company’s stock.

Analysts Set New Price Targets

Several analysts have issued reports on the company. Cantor Fitzgerald restated an “overweight” rating and issued a $13.00 price objective on shares of Humacyte in a research note on Friday, September 20th. Benchmark reaffirmed a “buy” rating and set a $15.00 price target on shares of Humacyte in a report on Thursday, September 5th. BTIG Research lifted their price objective on shares of Humacyte from $8.00 to $11.00 and gave the stock a “buy” rating in a research report on Monday, July 15th. Finally, EF Hutton Acquisition Co. I raised shares of Humacyte to a “strong-buy” rating in a research report on Monday, September 9th. One analyst has rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $9.80.

Humacyte Stock Up 1.0 %

HUMA opened at $5.50 on Wednesday. The stock has a fifty day moving average of $6.54 and a 200-day moving average of $5.71. The company has a market capitalization of $654.37 million, a P/E ratio of -5.44 and a beta of 1.47. Humacyte, Inc. has a fifty-two week low of $1.96 and a fifty-two week high of $9.97. The company has a debt-to-equity ratio of 0.61, a quick ratio of 5.41 and a current ratio of 5.41.

Humacyte (NASDAQ:HUMA) last issued its quarterly earnings data on Tuesday, August 13th. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.04). On average, equities analysts expect that Humacyte, Inc. will post -1.09 EPS for the current year.

Insider Activity at Humacyte

In other Humacyte news, Director Brady W. Dougan sold 352,112 shares of the firm’s stock in a transaction on Thursday, August 29th. The stock was sold at an average price of $6.35, for a total transaction of $2,235,911.20. Following the transaction, the director now owns 3,677,262 shares in the company, valued at approximately $23,350,613.70. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. In related news, Director Brady W. Dougan sold 252,676 shares of the company’s stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $6.71, for a total transaction of $1,695,455.96. Following the completion of the sale, the director now owns 4,306,464 shares of the company’s stock, valued at $28,896,373.44. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Brady W. Dougan sold 352,112 shares of the firm’s stock in a transaction dated Thursday, August 29th. The shares were sold at an average price of $6.35, for a total transaction of $2,235,911.20. Following the completion of the transaction, the director now directly owns 3,677,262 shares in the company, valued at $23,350,613.70. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 1,084,153 shares of company stock worth $6,869,996. Company insiders own 23.10% of the company’s stock.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.